Pemetrexed (disodium)

Pemetrexed (disodium)

• CAS Number: 150399-23-8
• UNSPSC Description: Pemetrexed disodium (LY231514 disodium) is an antifolate, the Kis of the pentaglutamate of Pemetrexed disodium are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively[1].
• Target Antigen: Antifolate; Apoptosis; Autophagy
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Pemetrexed-disodium.html
• Purity: 99.99
• Solubility: H2O : 100 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C1NC(N)=NC2=C1C(CCC3=CC=C(C=C3)C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)=CN2
• Molecular Weight: 471.37
• References & Citations: [1]Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.|[2]Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66.Beilstein J Org Chem. 2017 Oct 25;13:2252-2263.|Clin Transl Oncol. 2022 Jul 19.|Faculty of the Graduate School of Biomedical Sciences. The University of Texas Southwestern Medical Center. Oct 1. 2015.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Mol Cell. 2019 Dec 5;76(5):838-851.e5.|Odontology. 2020 Apr;108(2):300-311.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Ther. 2024 Jul 18.|bioRxiv. 2024 June 12.|Br J Cancer. 2023 Jun 27.|Cell Death Discov. 2022 Jul 5;8(1):307.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Commun Biol. 2022 Jun 23;5(1):619.|Heliyon. 2024 Nov 8;10(22):e40299.|Int Immunopharmacol. 2023 Nov 3;125(Pt A):111158.|Integr Cancer Ther. 2024 Jan-Dec:23:15347354241273962.|J Clin Invest. 2021 Aug 2;131(15):e138022.|J Control Release. 2022 Dec 9;353:490-506.|J Pharm Anal. 2024 Apr 25:100984.|Mol Cancer. 2024 Jan 10;23(1):12.|Pharmacol Res Perspect. 2020 Apr;8(2):e00575.|Pharmacol Res. 2024 May 9:204:107208.|Research Square Print. September 27th, 2022.|Theranostics. 2020 May 15;10(13):6048-6060.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched